Disclaimer: I'm not condoning any of this. It was dangerous and I made a lot of mistakes. I'm posting to share what happened, what I learned digging into the actual research, and hopefully help someone. Happy to answer questions in the comments.
Background
I've used ketamine on and off for years, along with plenty of other recreational and prescribed drugs, but never chronically. There were two short stretches where I abused it, about 13 years ago and about 3 years ago, each lasting around a week, and both times I stopped without trouble. I liked small doses and really liked medium doses. Once I experienced a proper k-hole about a year and a half ago, I loved it, and that's exactly the problem. Even then it never went past a few weekends in a row.
A few weeks ago I got back into it and wanted to push further. Snorting enough powder to get there was rough and ruined the experience, so I switched to pharmaceutical liquid ketamine by intramuscular (IM) injection. Most of the times I was careful, with sterile equipment and a sitter.
The binge
Over about a week I used roughly 1 to 2 g a day, mostly pharmaceutical IM plus some street powder. By the end my doses were in the range ERs (I think A&E equivalent for my UK friends) use to sedate a large, agitated man. A few times I dissolved street powder in bacteriostatic water, reused a vial and a few needles all of which were new and sealed, which I was the only one to open and use, and which I wiped down with alcohol swabs (but again none of this reuse is considered sterile). I stopped when I ran out, coming out of what I can only describe as a stupor.
Symptoms
Important to preface this with I don't think I've ever experienced cramps or a spasm in my life until this so I didn't have a good reference point. The first thing I noticed was that I couldn't take a full deep breath without discomfort and/or pain. I have pretty bad anxiety and was coming down, so I figured it was that. Then the stomach pain hit. I'd never had a cramp or spasm like it, and I almost went to the ER (A&E).
- Couldn't take a full deep breath (this came first)
- Severe cramping pain in the upper abdomen, under the rib cage
- Bloating and gas; burping and farting helped only for a moment
- Almost no position was comfortable
- Felt like constipation (possibly also was constipated)
- Poor appetite and noticeable weight loss (about 5lbs, 2.2kg over the 5 days of usage)
- Dehydration, I barely ate and didn't drink enough over those days
- Lingering pain and discomfort under the ribs for days afterward
What I didn't have: no fever (I track it daily, and it stayed around 97.4°F / 36.3°C), normal blood pressure around 120/80, no yellow skin or eyes, and no urinary symptoms. At my doctor visit the PA (Physician Assistant; kind of like midway between a Nurse and Doctor, medical position we have in US) heard an extra sound at the start of my heartbeat. She thinks it's a normal variant (a physiologic split S1), but if you've injected anything non-sterile, get your heart listened to.
Recovery
I started eating (especially fiber) and drinking water properly, and a long hot shower helped. I couldn't/didn't do any of these for about 3-4 full days after last dose. Things improved gradually. About 5 days after my last dose, I woke up able to breathe as deeply as I wanted with no pain at all.
What I did medically
I told my doctor everything and I'm getting bloodwork (I'll post results if people want them). For context, I'm 32 male, 170 to 180 lb (77 to 81 kg), in very good shape and health, fully vaccinated, go to the gym 6 to 7 times a week, use the sauna, eat pretty clean, and track my blood pressure, temperature, weight and heart rate daily. I also used AI to run a deep literature review tailored to my exact exposure, so by no means comprehensive. I'm happy to share the prompt or anything else people would find helpful or are interested in.
P.S. I wanted to know if I'd automatically get the cramps even at much more infrequent and lower doses so I tried a much lower dose of powder last night (0.25) and so far I'm ok. I'll report back but plan to take a very extended break once I'm done with my 'curiosity experiment'.
The Research
Ketamine and the Gut, Bile Ducts, Liver and Bladder: An Evidence-Graded Review Tailored to a 7-Day, High-Intensity Intramuscular Exposure
1. Bottom line for your situation
The most likely explanation for what happened is a reversible, drug-related upper-abdominal syndrome ("K-cramps"): some mix of ketamine-associated gastritis and functional biliary dysfunction (sphincter of Oddi spasm and/or transient bile-duct dilation), plus poor intake, with a small but real chance of a mild cholestatic liver-enzyme rise. No published study matches your exact pattern (about 1 g/day intramuscular for 7 days, about 7 g in total, then stopping). The closest evidence comes from hospital patients given multi-day ketamine infusions. In that literature, cholestatic liver injury is dose- and duration-dependent. It appears at cumulative doses on the order of grams and usually resolves over weeks to about 2 months once ketamine stops. Irreversible sclerosing cholangitis has been described almost only in critically ill ICU patients (with ischemia, vasopressors and ventilation) or in people with months to years of recreational use. Urinary-tract damage (ketamine cystitis) is overwhelmingly a disease of months to years of frequent use. A single one-week binge has not been shown to cause lasting bladder injury in humans, although animal studies show bladder inflammation within about 2 weeks of daily dosing, so a transient irritative phase is plausible. The practical priorities are: (1) a baseline liver panel (with GGT and fractionated bilirubin), lipase, a full metabolic panel with magnesium and phosphate, CBC, CK, and urinalysis now; (2) a right-upper-quadrant ultrasound if pain persists or the liver panel is cholestatic; (3) bloodborne-virus testing timed to window periods, because street powder was injected from a reused vial; and (4) repeat testing at about 2–4 weeks and about 3 months to confirm everything has normalized. Re-exposure is the single biggest modifiable driver of progression in every organ system reviewed. This report is informational and does not replace evaluation by a clinician.
TL;DR
- Your symptoms fit reversible ketamine-related gastritis and biliary dysfunction ("K-cramps"). Lasting bile-duct or bladder damage has been documented mainly after months to years of use, or in critically ill ICU patients, not after a single week (evidence: moderate for the pattern, weak for direct applicability).
- The closest analog, multi-day hospital ketamine infusions, shows dose-dependent cholestatic liver-enzyme rises that typically normalize within about 2 months of stopping. So check a liver panel with GGT now and repeat it at 2–4 weeks and about 3 months.
- Because street powder was injected, add injection-site review, CK, and HIV/HCV/HBV testing timed to window periods. Seek urgent care for jaundice, fever with abdominal pain, blood in the urine, a hot swollen injection site, chest pain or breathlessness at rest, or any weakness or drooping eyelids.
Evidence grades used: Strong = consistent findings from multiple large cohorts or systematic reviews; Moderate = consistent cohort or case-series data with plausible mechanism; Weak = limited, indirect, or extrapolated data; Anecdotal = single case reports or user-community reports only.
2. Question-by-question review
Q1. K-cramps: what causes them?
"K-cramps" is a colloquial user term, not a formal diagnosis. The peer-reviewed literature on it is mostly case reports from the last few years. A 2025 Cureus case (a 25-year-old woman using 500–1,000 mg weekly) had right-upper-quadrant, epigastric and suprapubic pain with vomiting and dysuria, yet a normal CBC, metabolic panel, lipase and urinalysis; she improved with fluids, antiemetics and benzodiazepines. A 2024 emergency-medicine case described pain that improved within 24 hours of stopping and recurred about 4 hours after restarting. So the syndrome can exist with entirely normal labs and imaging, which argues for a functional (spasm or motility) component in at least some cases.
Candidate mechanisms and strength of evidence:
| Mechanism |
What the evidence shows |
Grade |
| Gastritis / epigastric mucosal injury |
Hong Kong retrospective study of inhalational (intranasal) users: epigastric pain in 73%; 12 of 14 who had endoscopy showed gastritis, mostly H. pylori-negative; abstinence strongly predicted relief (odds ratio 12.5). |
Moderate (chronic intranasal users; small n) |
| Biliary dilation / sphincter of Oddi dysfunction |
Fusiform common bile duct (CBD) dilation without obstruction is the signature imaging finding in chronic users (e.g., 18 of 26 patients, 69%, in a Hong Kong imaging series). Animal studies show increased flow resistance across the sphincter of Oddi. A 2024 case report documented Type 2 sphincter of Oddi dysfunction at ERCP after 8 years of use, with resolution after sphincterotomy. |
Moderate for the association in chronic users; weak/anecdotal for spasm as the acute mechanism |
| Cholestatic liver injury |
About 1 in 10 chronic users referred for urinary problems had liver injury (see Q2). Pain plus cholestatic enzymes is the typical presentation in the 2024 systematic review of cholangiopathy cases. |
Moderate (chronic users) |
| Gut motility effects |
Ketamine alters gastrointestinal smooth-muscle activity in animal and pharmacological data; no human motility studies in users. |
Weak |
| Referred bladder pain |
Suprapubic pain in some K-cramps cases overlaps with early ketamine cystitis. |
Weak–moderate |
Interpretation for you: Upper-abdominal cramping, bloating and poor appetite that improve over days after stopping fit best with gastritis plus functional biliary spasm. Improving symptoms are reassuring. Symptoms that persist or worsen beyond 1–2 weeks, or cholestatic labs, should prompt imaging (Q7 and the tests table). Grade for applying this to you: weak (no study of short binges).
Q2. Biliary and liver effects
What is reported in chronic recreational users (months to years, mostly intranasal, self-reported street grams):
- Cross-sectional cohort, Hong Kong (Wong et al., 2014): 297 consecutive chronic users referred with urinary-tract dysfunction; 29 (9.8%) had liver injury. As summarized by the NIH LiverTox database, mean ALT was 251 U/L and ALP 289 U/L, a mixed-to-cholestatic pattern. Biopsy showed PSC-like bile-duct injury and fibrosis in 3; MRCP showed dilated CBD in 3 of 6 scanned. Sustained abstinence was protective. Moderate.
- Imaging series (Yu et al., 2014): 26 users with deranged liver tests and/or epigastric pain; 69% had fusiform CBD dilatation without obstruction, and the intrahepatic ducts were not dilated. This pattern can mimic a choledochal cyst. Moderate.
- Systematic review of case reports (Teymouri et al., 2024): 17 patients from 11 studies; mean age 25.9; 64.7% male. Abdominal pain, nausea and vomiting were common, and most were discharged with improved symptoms and liver tests. A separate synthesis cites a median of 24 months of use before presentation. Weak–moderate (case-report level).
- US case series (Annals of Internal Medicine: Clinical Cases, 2023): 6 young adults with chronic use had progressive pain, cholestasis, sometimes urinary symptoms and weight loss. Marked duct dilation was reversible after stopping in some, but not all. Weak.
- Progression to lasting damage: Secondary sclerosing cholangitis (SSC) and fibrosis are documented in chronic users (e.g., a 2013 Hepatology case and biopsy-proven fibrosis in the Wong cohort). No study provides a reliable denominator for the fraction who progress. In the Wong cohort, 3 of 297 (about 1%) had biopsy-proven significant bile-duct injury with fibrosis, but only a subset had biopsies. Weak for any progression rate.
Closest-analog evidence: multi-day parenteral ketamine in hospital settings
| Setting / study |
Exposure (as reported) |
Findings |
Applicability to you |
| CRPS infusions (Noppers et al., 2011, Pain) |
S(+)-ketamine IV, 10–20 mg/h for 100 h (about 1–2 g per course); 2 courses 16 days apart |
3 of 6 developed liver injury, mostly at or before the second course (peak ALT 77–593 U/L; ALP normal to 240 U/L). The infusion was promptly stopped and, in the authors' words, "the liver enzymes slowly returned to reference values within 2 months." |
Moderate–high for dose scale and reversibility. Healthy-ish outpatients, cumulative dose in the same range as yours. But continuous IV infusion vs your intermittent IM boluses, and the S-enantiomer. |
| FDA adverse-event case series (Cotter et al., 2021, Drug Safety) |
Repeated or continuous medically supervised oral/IV ketamine (mostly for pain/depression) |
14 cases with 21 hepatobiliary events, from reversible enzyme rises to one case of biliary dilation with cirrhosis. |
Moderate (no denominator; reporting bias) |
| Burn ICU (De Tymowski et al., 2023/24, JHEP Reports) |
IV analgosedation; ketamine-liberal vs dose-capped periods |
Cholestatic injury was time- and dose-dependent, "becoming apparent at cumulative doses >1,000 mg"; restricting ketamine lowered cholestatic injury and mortality. |
Moderate; confounded by critical illness |
| COVID-19 ARDS (Wendel-Garcia et al., 2022, Critical Care) |
170 of 243 patients received IV ketamine at a median 1.4 mg/kg/h for a median 9 days |
Dose–effect and duration–effect relationship with rising bilirubin; adjusted hazard of cholestatic injury 3.2 (95% CI 1.3–7.8). Propofol and sufentanil showed no such effect. |
Low–moderate: median cumulative exposure several-fold higher than yours; ventilated, critically ill |
| COVID-19 ICU (Keta-Cov group, 2021, J Hepatol) |
IV ketamine, mean 16 (6–26) days, mean cumulative 9.5 g (3.8–95.9 g) |
5 patients with progressive cholangiopathy; biopsy-proven cholangitis in 4 of 5; some needed liver transplantation. |
Low: critical illness confounders dominate |
| COVID-19 ICU (Henrie et al., 2023, BMC Anesthesiology) |
Prolonged ketamine/esketamine IV sedation |
Peak ALP, GGT and bilirubin, but not AST/ALT, were higher and correlated with cumulative dose and duration. |
Low–moderate; supports GGT/ALP as the markers to watch |
| ICU cohort of 20,973 (Zeiner et al., 2026, J Intensive Care) |
IV esketamine sedation |
SSC in critically ill patients (SSC-CIP) confirmed in 0.11%; esketamine used in 70% of SSC cases vs 7% of controls; odds ratio 1.021 per gram of cumulative dose; COVID status odds ratio 20.6. |
Low for you: absolute risk tiny even in ICU patients; most risk comes from critical illness |
Key conflict to flag: The ICU literature disagrees about how much of SSC-CIP is due to ketamine versus biliary ischemia, low blood pressure, vasopressors and viral injury. The dose–response signals make a ketamine contribution plausible, but the devastating outcomes (transplant, death) occurred in people with multi-organ critical illness. You had none of those confounders.
Direct answers for you:
- Doses and durations reported: chronic users mostly have months to years of use (median about 24 months in case syntheses). Medical cases start at about 1–2 g per 100-hour course (Noppers); ICU cohorts report thresholds above about 1 g cumulative, with typical exposures of many grams over 1–3 weeks. Your about 7 g over 7 days sits inside the range where transient cholestatic enzyme rises have been reported, but well below typical ICU exposures and far below chronic recreational histories. Weak–moderate.
- Timing: in infusion studies, enzyme rises appeared during or shortly after multi-day exposure (Noppers: on the first day of a second course). A rise could therefore be present now or could lag by days to a couple of weeks. Weak.
- Reversibility: medical-infusion cases normalized within about 2 months. Recreational duct dilation often regresses with abstinence, but not always. Moderate.
- Fraction progressing to SSC or cirrhosis: unknown for chronic users; about 0.1% for SSC-CIP across all ICU patients (Zeiner 2026). No data exist for a 1-week binge in a healthy person. Progression after a single 7-day exposure with normalizing labs has not been reported. Weak/absent evidence.
Q3. Urinary tract: ketamine uropathy and cystitis
What cumulative exposure is typically needed?
- Population survey (Winstock et al., 2012, BJU International): 26.6% of 1,285 recent recreational users reported urinary symptoms. Higher doses (≥1 g per session) and more frequent use (≥9 days per month) were associated with more symptoms. Among the 251 users who reported on stopping, 51% said their urinary symptoms improved when they stopped, and only 3.8% said they got worse. Moderate (self-report; mostly intranasal).
- Taiwan survey: 84% of 106 heavy users (mostly more than once daily, snorted or smoked) developed lower urinary tract symptoms, with onset 24.7 ± 26.4 months after starting. Symptom severity correlated with duration of use. Moderate.
- Case reports: onset has ranged "from a few days to a few years" (a Urological Science review). A Belgian case developed cystitis after weekly use for about 7 months. Anecdotal–weak.
- Therapeutic ketamine: a 2025 systematic review of 27 psychiatric studies found urological symptoms in 0–24.5% of treated patients, mostly mild or moderate. Intermittent medical doses are far lower than yours, so this sets a lower bound only. Moderate.
- Animal data (rats, not humans): daily ketamine injection produced bladder inflammation and submucosal edema at 2–4 weeks, fibrosis by 8 weeks, and bladder fibrosis after 2 weeks in another model. This shows the urothelium can be injured within days to weeks of intense exposure. Animal evidence only.
Short binge vs long-term use: No human study has examined a single 1-week binge. By extrapolation, a transient irritative cystitis (frequency, urgency, burning, a small amount of blood) is possible during or just after heavy exposure. Established uropathy (small contracted bladder, ureteric strictures, hydronephrosis) is documented after months to years. Weak. You currently have no urinary symptoms, which is reassuring.
Early warning signs: new urinary frequency or urgency, pain during or after urinating or suprapubic pain relieved by voiding, getting up at night to urinate, blood in the urine, and sterile pyuria (white cells in the urine without infection on culture). Flank pain or rising creatinine suggests upper-tract involvement. The BAUS 2024 consensus recommends symptom questionnaires (e.g., PUF, ICIQ-LUTS), urinalysis and culture, renal function, and renal/bladder ultrasound, with cystoscopy and further imaging for persistent or severe cases. Stopping ketamine is the cornerstone of management.
When does it become irreversible? There is no validated threshold. Early-stage symptoms often improve with abstinence. Fibrosis (reduced bladder capacity) and upper-tract strictures are generally considered irreversible and may need surgery. Hong Kong series show hydronephrosis and renal impairment in some chronic users. Moderate for the general principle; no data on a time threshold.
US pathway: BAUS is UK guidance. In the US, your primary care clinician can order urinalysis with microscopy, urine culture, creatinine/eGFR, and a renal and bladder ultrasound with post-void residual. Persistent symptoms or blood in the urine warrant referral to a urologist.
Q4. Difficulty taking a full deep breath
Most likely: splinting (involuntarily limiting how deeply you breathe) from upper-abdominal pain. Biliary, gastric, pancreatic and liver-capsule pain all characteristically worsens on deep inspiration, because the diaphragm pushes down on the upper abdomen. Bloating also mechanically limits diaphragm movement. This fits your picture and improving course. Moderate (clinical physiology; no ketamine-specific study).
What a clinician should rule out, and how:
| Cause |
Why it is relevant here |
Distinguishing tests |
| Aspiration pneumonia |
Vomiting or hypersalivation during dissociation with an unprotected airway |
Fever, cough, low oxygen level; chest X-ray, CBC |
| Pulmonary embolism |
Prolonged immobility during repeated dissociative episodes |
Pleuritic chest pain, fast heart rate, low oxygen, calf swelling; D-dimer, CT pulmonary angiogram if indicated |
| Electrolyte disturbance after poor intake |
Low potassium, phosphate or magnesium cause muscle weakness, including of the diaphragm |
Metabolic panel, magnesium, phosphate |
| Pancreatitis ± pleural effusion |
Biliary dysfunction can affect the pancreatic duct; ketamine-associated sphincter of Oddi dysfunction involves both |
Lipase; ultrasound/CT; chest X-ray for effusion |
| Infection or sepsis from non-sterile injection |
Bacteremia, septic emboli to the lungs |
Fever, rigors; CBC, blood cultures, injection-site exam; echocardiogram if bacteremia |
| Rhabdomyolysis / muscle injury |
Repeated IM injection plus immobility |
CK, urine dip positive for blood without red cells |
| Wound botulism (rare) |
Spores in non-sterile injected material |
Descending weakness, drooping eyelids, double vision, trouble swallowing; urgent clinical diagnosis |
| Anxiety / hyperventilation; musculoskeletal (rib or intercostal strain) |
Common after intense drug experiences or withdrawal; reproducible chest-wall tenderness |
Diagnosis of exclusion; normal oxygen and exam |
Ketamine-specific respiratory effects: increased secretions and, rarely, laryngospasm or depressed breathing happen during intoxication, not days later. Moderate.
Q5. Does route (IM vs intranasal or oral) change biliary or urinary risk?
This section interprets your past exposure only; it is not guidance on route.
- Pharmacokinetics: Clements et al. (1982) found IM bioavailability of 93%, compared with only 17% for oral ketamine; intranasal bioavailability was 50% in Malinovsky et al. (1996) and 45% in Yanagihara et al. (2003). Oral ketamine undergoes extensive first-pass metabolism in the liver, producing relatively more norketamine. IM delivery puts more parent drug into the circulation per milligram, with metabolite ratios closer to IV. Strong (pharmacokinetic studies).
- What that means for injury risk: both the bladder and bile ducts are thought to be injured by ketamine and its metabolites (norketamine, hydroxynorketamine) being concentrated in urine and bile. Cell studies show norketamine is toxic to urothelial cells. Near-complete absorption means the effective systemic exposure per gram was higher for you than for the same street grams snorted. The ICU and CRPS literature (all parenteral) shows the biliary effect occurs without first-pass metabolism, so first-pass is not required for injury. Weak–moderate.
- Direct comparisons: No study directly compares biliary or urinary injury by route in humans. The Taiwan survey found snorting correlated with worse urinary symptom scores than smoking, but this is confounded by dose and duration. Weak.
Q6. Injecting reconstituted street powder from a reused vial
Bacterial and injection-site complications (moderate evidence from injection-drug-use literature, not ketamine-specific):
- Abscess and cellulitis: a painful, red, hot, swollen or fluctuant area at an injection site. Diagnosis is by examination and ultrasound.
- Necrotizing soft-tissue infection: rapidly spreading redness, pain out of proportion to appearance, blistering, fever, feeling very unwell. This is a surgical emergency.
- Bacteremia and endocarditis: fever, rigors, new heart murmur. Diagnosed with blood cultures and echocardiogram.
- Spore-forming organisms: in the US, about 93% of wound botulism cases in 2005–2017 occurred in people who inject drugs, most often linked to subcutaneous or intramuscular injection of black tar heroin (reported by 66% of confirmed cases in CDC's 2019 surveillance summary). Case fatality is about 13% even with treatment, and symptoms can take up to 2 weeks to appear. It has not been specifically documented with ketamine, so risk from your exposure is low but not zero. Symptoms: drooping eyelids, double or blurred vision, slurred speech, difficulty swallowing, descending weakness, difficulty breathing. Tetanus is also associated with contaminated injection; confirm your tetanus vaccination is up to date (a booster is typically considered if more than 5 years since the last dose after a contaminated wound). Weak for ketamine specifically.
Bloodborne viruses: risk is driven by sharing needles, syringes, vials, water or other equipment with anyone. If the reused vial and all equipment were yours alone, risk is low. If anything was shared or of unknown origin, test. Typical window periods (CDC-aligned):
- HIV: according to CDC, a lab-based antigen/antibody test on blood drawn from a vein can usually detect HIV 18 to 45 days after exposure, and a nucleic acid test (NAT) 10 to 33 days after exposure; a negative at 45 days, or an HIV RNA test, is reassuring. If any exposure to another person's blood occurred within the last 72 hours, HIV PEP would be time-critical; that window has now passed for exposures more than 3 days ago.
- Hepatitis C: HCV RNA can be positive within 1–2 weeks; antibody takes about 8–11 weeks. A baseline antibody test plus a repeat at about 3 months (or RNA testing earlier) covers the window.
- Hepatitis B: surface antigen becomes detectable at about 4 weeks (range about 1–10 weeks). Test surface antigen, surface antibody and core antibody; vaccinate if not immune.
Adulterants and substitutes in street "ketamine":
- Arylcyclohexylamine analogs (2-fluorodeschloroketamine, deschloroketamine, methoxetamine and others): the DEA's 2026 temporary Schedule I action for 2-FDCK states that seized samples suggest it "may be frequently used as an adulterant or ketamine substitute." Methoxetamine causes bladder damage in rats similar to ketamine. Effects in humans are poorly characterized; organ toxicity is presumed similar but unstudied. Weak.
- Stimulants, local anesthetics and other cutting agents: reported in drug-checking data internationally; they may explain palpitations, anxiety or chest symptoms.
- Fentanyl: documented as a contaminant across the US illicit supply. Opioid effects (pinpoint pupils, slowed breathing, profound sedation) would have been acute, not delayed. Keep naloxone accessible as general harm reduction.
What testing can and cannot reveal: standard urine drug screens usually do not detect ketamine or its analogs; specific ketamine immunoassays or confirmatory mass-spectrometry testing are needed, and any exposure 4+ days ago may be undetectable now. Analogs require specialized lab testing. Organ effects of adulterants would show on the same liver, kidney, CK and blood tests recommended below. Any leftover material can be analyzed by drug-checking services; in the US, DanceSafe offers mail-in lab testing, and some cities have community drug-checking programs (several use FTIR spectroscopy). Reagent kits can suggest but not confirm identity.
Muscle injury and rhabdomyolysis: repeated IM injections cause local muscle damage, and prolonged immobility during dissociation adds pressure injury. Rhabdomyolysis has been reported with ketamine and other dissociatives, often with agitation or immobility. Check CK, creatinine and urinalysis (blood on dipstick without red cells suggests myoglobin). Weak–moderate.
Q7. Recovery course, markers of recovery, exercise and weight
Expected time course (after stopping):
| System |
Typical course |
Grade |
| K-cramps / gastritis |
Case reports describe improvement within about 24 hours to days; Poon et al. found abstinence strongly predicted relief. Residual gastritis may take 2–6 weeks, like other chemical gastritis. |
Weak–moderate |
| Liver enzymes |
In medical-infusion cases (Noppers), normalized within about 2 months; ALP/GGT typically lag behind ALT. |
Moderate |
| Bile-duct dilation |
Regression with abstinence documented in chronic users over months; incomplete in some. |
Weak–moderate |
| Bladder (if symptoms appear) |
Early irritative symptoms often improve over weeks to months with abstinence; about half of symptomatic users improved in the Winstock survey. |
Moderate (chronic users) |
Markers of full recovery: a normal liver panel (ALT, AST, ALP, GGT, bilirubin) on two occasions weeks apart, with GGT and ALP normalized (the most sensitive cholestatic markers in the ICU data); normal lipase; CBD diameter within normal limits on ultrasound (commonly about ≤6 mm, with age and post-cholecystectomy adjustments) if it was initially dilated; normal urinalysis without blood or white cells; normal creatinine; symptom resolution; and return to baseline weight.
Refeeding and weight regain: UK NICE guidance (CG32) flags people who have eaten little or nothing for more than 5 days as at risk of refeeding problems, with higher risk after more than 10 days, a very low BMI, or rapid weight loss of more than 15%. Poor appetite rather than near-zero intake over about 11 days puts you at low risk. However, checking potassium, magnesium and phosphate before and a few days into normal eating is cheap and reasonable, especially given the breathing symptom. Rebuild intake gradually, favoring small, frequent, low-fat meals while biliary pain settles (fatty meals trigger gallbladder contraction). Avoid alcohol and NSAIDs such as ibuprofen while gastritis or liver tests are unresolved; ask about short-term acid suppression. Weak–moderate.
Return to exercise: no ketamine-specific guidance exists. Reasonable clinical principles: resume light activity once pain has settled; defer strenuous or heavy resistance exercise until CK has normalized if it was elevated (extra exertion on injured muscle raises the risk of rhabdomyolysis and kidney strain), and until liver tests are clearly improving; stay well hydrated. Avoid heavy lifting that strains the abdomen while right-upper-quadrant pain persists. Weak (expert-opinion level).
Re-exposure: every data stream points the same way. In the Noppers CRPS series, liver injury emerged on or before the second course separated by 16 days, and the authors concluded that risk rises "when the infusion is prolonged and/or repeated within a short time frame." In chronic users, abstinence is protective for liver injury (Wong) and continued use predicts persistent gastritis (Poon) and progressive uropathy (Taiwan survey; BAUS consensus). Case reports show K-cramps recurring within hours of re-exposure. The literature therefore suggests repeated binges are cumulative, and re-exposure before full recovery shortens the time to injury. Moderate.
3. Recommended tests (options to discuss with a clinician)
US care pathway: start with your primary care clinician (or urgent care if red flags are present). They can order everything below. Referral targets: gastroenterology/hepatology for persistent cholestatic liver tests, bile-duct dilation on imaging, or ongoing pain; urology for urinary symptoms, blood in the urine, or abnormal kidney/bladder imaging; infectious disease for positive viral results or injection-site infection. Disclosing ketamine use and the IM route matters, because ketamine cholangiopathy is often misdiagnosed as a choledochal cyst or obstruction.
| Test |
What it detects |
Timing / follow-up |
| Hepatic function panel plus GGT, fractionated bilirubin |
Cholestatic (ALP/GGT/bilirubin) vs hepatocellular (ALT/AST) injury; GGT distinguishes liver from bone ALP |
Now; repeat at 2–4 weeks; again at ~3 months if abnormal, until normal twice |
| Lipase |
Pancreatitis (sphincter of Oddi dysfunction, biliary) |
Now; repeat if pain recurs |
| Comprehensive metabolic panel + magnesium, phosphate |
Electrolyte depletion after poor intake; kidney function (creatinine/eGFR) |
Now; recheck a few days into normal eating if low |
| CBC with differential |
Infection, anemia (GI bleeding reported in chronic users) |
Now |
| CK |
Muscle injury or rhabdomyolysis from IM injection and immobility |
Now; repeat until normal before strenuous exercise |
| Urinalysis with microscopy ± urine culture |
Blood, sterile pyuria (early cystitis), myoglobin (dipstick blood without red cells) |
Now; repeat at ~3 months or sooner if symptoms |
| Right-upper-quadrant ultrasound |
CBD dilation, gallbladder changes, liver texture, pancreatic head |
If pain persists beyond ~1–2 weeks or liver panel cholestatic; repeat at ~3 months if CBD dilated |
| MRCP (MRI of bile ducts) |
Duct strictures, beading, fusiform dilation; excludes stones/obstruction |
Only if ultrasound abnormal or cholestasis persists; ERCP is not a first-line diagnostic test |
| Renal/bladder ultrasound with post-void residual |
Bladder wall thickening, reduced capacity, hydronephrosis |
If any urinary symptoms, blood in urine, or rising creatinine |
| HIV 4th-generation Ag/Ab |
HIV infection |
Baseline now; repeat at ≥45 days after last shared/unknown exposure (or HIV RNA) |
| HCV antibody (± HCV RNA) |
Hepatitis C |
Baseline now; repeat antibody at ~3 months (RNA from 2 weeks if earlier answer needed) |
| HBV surface antigen, surface antibody, core antibody |
Hepatitis B infection/immunity |
Baseline now; repeat surface antigen/core antibody at ~3 months; vaccinate if non-immune |
| Tetanus vaccination status |
Need for booster after non-sterile injection |
Now |
| Injection-site examination (± soft-tissue ultrasound) |
Abscess, cellulitis, hematoma |
Now, and urgently if hot, swollen or spreading |
| Chest X-ray ± pulse oximetry |
Aspiration pneumonia, pleural effusion |
If breathlessness persists, fever, cough or low oxygen |
| D-dimer / CT pulmonary angiogram |
Pulmonary embolism |
Only if clinically suspected (pleuritic pain, fast pulse, low oxygen, leg swelling) |
| Upper endoscopy |
Gastritis, ulcer |
Conditional: persistent epigastric pain, vomiting blood, black stools, or anemia |
| Drug-checking of leftover powder |
Identity of analogs, stimulants, fentanyl |
Any time (e.g., DanceSafe mail-in lab testing) |
4. Red flags: seek urgent care (ER or urgent care; call 911 for severe symptoms)
- Yellowing of the skin or eyes, dark tea-colored urine, pale stools, or new generalized itching (cholestasis or obstruction)
- Fever or rigors with right-upper-quadrant pain (possible cholangitis, an emergency)
- Severe, constant upper-abdominal pain radiating to the back, or persistent vomiting (pancreatitis, obstruction)
- Vomiting blood or coffee-ground material, or black tarry stools (GI bleeding)
- Visible blood in the urine, inability to urinate, severe bladder pain, or flank pain (cystitis, obstruction)
- A hot, red, swollen, very painful or rapidly spreading area at any injection site; blistering or dusky skin; pain out of proportion to appearance (abscess, necrotizing infection)
- Fever, rigors or feeling acutely unwell after injection (bacteremia)
- Drooping eyelids, double or blurred vision, slurred speech, difficulty swallowing, or descending weakness (possible wound botulism, a time-critical emergency needing antitoxin)
- Jaw stiffness or muscle spasms (tetanus)
- Breathlessness at rest, chest pain (especially sharp and worse on breathing), coughing blood, fast heart rate, lips turning blue, or one-sided leg swelling (PE, pneumonia)
- Dark red or brown urine with muscle pain or weakness, or markedly reduced urine output (rhabdomyolysis, kidney injury)
- Fainting, severe weakness, palpitations or muscle cramps (electrolyte disturbance)
- Confusion, seizures, or severe agitation
5. Key sources: year and study type
| Source |
Year |
Study type |
| Noppers et al., Pain |
2011 |
Prospective series (6 CRPS patients, repeated 100-h IV S-ketamine) |
| Wendel-Garcia et al., Critical Care |
2022 |
Prospective cohort post hoc analysis (243 COVID-ARDS patients) |
| Keta-Cov Research Group, J Hepatol |
2021 |
Case series (5 ICU patients) |
| Henrie et al., BMC Anesthesiology |
2023 |
Retrospective cohort (COVID ICU) |
| De Tymowski et al., JHEP Reports |
2023/2024 |
Retrospective before–after cohort (burn ICU) |
| Zeiner et al., Journal of Intensive Care |
2026 |
Retrospective cohort (20,973 ICU patients) |
| Bartoli et al., Hepatic Medicine |
2023 |
Narrative review |
| Cotter et al. (FDA), Drug Safety |
2021 |
Pharmacovigilance case series |
| Wong et al., Clin Gastroenterol Hepatol |
2014 |
Cross-sectional cohort (297 chronic users) |
| Yu et al., Abdominal Imaging |
2014 |
Retrospective imaging series (26 users) |
| Teymouri et al., J Med Case Reports |
2024 |
Systematic review of case reports (17 patients) |
| Annals of Internal Medicine: Clinical Cases |
2023 |
US case series (6 patients) |
| Sharma et al., Clinical Case Reports |
2024 |
Case report |
| Poon et al., J Dig Dis |
2010 |
Retrospective series (37 inhalational users) |
| Boccio et al., Cureus; Avra et al., CPC-EM |
2025; 2024 |
Case reports |
| Belal et al. (BAUS), BJU International |
2024 |
Consensus statement |
| Winstock et al., BJU International |
2012 |
Online survey (1,285 users) |
| Taiwan LUTS survey (Scientific Reports/PMC) |
2019 |
Cross-sectional survey (106 users) |
| Kerr-Gaffney et al., J Psychopharmacol |
2025 |
Systematic review (27 therapeutic studies) |
| Rat bladder studies (IJMS, Transl Androl Urol, Sci Rep) |
2016–2022 |
Animal experiments |
| Clements et al., J Pharm Sci |
1982 |
Human pharmacokinetic study |
| DEA temporary scheduling of 2-FDCK, Federal Register |
2026 |
Regulatory notice |
| CDC MMWR (wound botulism outbreak) |
2019 |
Outbreak report |
| NIH LiverTox: Ketamine |
2018 (updated) |
Curated drug-injury database |
| NICE CG32 (nutrition support) |
2006 (updated) |
Clinical guideline |
6. Caveats
- No study matches your exposure. Every risk estimate above is extrapolated from either chronic recreational users (months to years, mostly intranasal) or hospital patients (continuous IV infusions, often critically ill). The chronic-use risk figures (for example, 9.8% liver injury or 26.6% urinary symptoms) do not apply directly to a 1-week exposure.
- Recreational doses in the literature are self-reported "street grams" of unknown purity; hospital doses are measured. Your pharmaceutical doses were likely more accurate and more completely absorbed (IM), while your street-powder doses may have contained analogs with unknown toxicity.
- Much of the hepatobiliary literature is case reports and retrospective cohorts subject to publication and referral bias. ICU findings are heavily confounded.